Revance Therapeutics (RVNC) Misses Q1 EPS by 9c

Revance Therapeutics (NASDAQ: RVNC) reported Q1 EPS of ($0.94), $0.09 worse than the analyst estimate of ($0.85). Revenue for the quarter came in at $75 thousand versus the consensus estimate of $70 thousand.

For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.

You May Also Be Interested In

• Kroger (KR) Reports In-Line Q1 EPS, Beats on Revenue; Offers FY27 EPS Guidance
• Hyperscale Data launches $300M at-the-market stock offering
• JPMorgan Upgrades SHIFT UP Corp (462870:KS) to Overweight